A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as monotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD) - Traboulsee, A; Greenberg, B; Bennett, J L (ECTRIMS Online Library, 2019)
(229118):